Edition:
United States

Zealand Pharma A/S (ZELA.CO)

ZELA.CO on Copenhagen Stock Exchange

127.00DKK
24 May 2017
Change (% chg)

-- (--)
Prev Close
kr.127.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
137,843
52-wk High
kr.137.50
52-wk Low
kr.85.50

Latest Key Developments (Source: Significant Developments)

Zealand Pharma: positive Phase 2a results with microdoses of dasiglucagon
Tuesday, 23 May 2017 02:40am EDT 

May 23 (Reuters) - ZEALAND PHARMA A/S :POSITIVE PHASE 2A RESULTS WITH MICRODOSES OF DASIGLUCAGON SUPPORT USE IN A DUAL-HORMONE ARTIFICIAL PANCREAS SYSTEM.DATA FROM THIS FIRST PHASE 2A TRIALS INDICATE THAT DASIGLUCAGON INCREASES BLOOD SUGAR LEVELS ACROSS ALL TESTED DOSE LEVELS.RESULTS FROM SECOND PHASE 2A TRIAL ON USE OF DASIGLUCAGON IN DUAL-HORMONE ARTIFICIAL PANCREAS SYSTEM, ILET(TM), ARE EXPECTED AT END OF JUNE 2017.  Full Article

Zealand Q1 net loss DKK 26.3 million
Wednesday, 17 May 2017 09:04am EDT 

May 17 (Reuters) - ZEALAND PHARMA A/S :REG-ZEALAND REPORTS RESULTS FOR THE FIRST THREE MONTHS OF 2017 (UNAUDITED).Q1 REVENUE OF DKK 77.6 MILLION (6.7 MILLION IN Q1 2016), INCLUDING MILESTONE REVENUE OF DKK 69.6 MILLION.Q1 NET LOSS DKK 26.3 MILLION VERSUS LOSS DKK 77.8 MILLION YEAR AGO.SAYS PHASE 2 TRIAL INVESTIGATING GLEPAGLUTIDE FOR THE TREATMENT OF SHORT BOWEL SYNDROME COMPLETED. RESULTS ARE EXPECTED BY END JUNE 2017.  Full Article

Zealand Pharma Q1 royalty revenue DKK 8.0 million
Friday, 28 Apr 2017 02:10am EDT 

April 28 (Reuters) - ZEALAND PHARMA A/S :ZEALAND REPORTS ROYALTY REVENUE OF DKK 8.0 MILLION IN Q1 2017.DKK 5.1 MILLION ARISES FROM ROYALTIES ON SALES OF LYXUMIA®/ADLYXIN.DKK 2.9 MILLION ARISES FROM ROYALTIES ON FIRST SALES OF SOLIQUA 100/33 IN U.S.  Full Article

Zealand Pharma FY revenue DKK 234.8 million, up 25 percent
Wednesday, 15 Mar 2017 09:49am EDT 

Zealand Pharma A/S : FY revenue 234.8 million Danish crowns ($33.53 million)versus 187.7 million crowns year ago . FY operating loss 115.6 million crowns versus loss 81.3 million crowns year ago . Says net operating expenses in 2017 are expected to be within the range 390-410 million crowns .Operating loss before royalty income/expenses is expected to be within 290-310 million crowns, excluding royalty revenue.  Full Article

Zealand Pharma royalty revenue of DKK 5.3 mln in Q4 on sales of Lyxumia
Wednesday, 8 Feb 2017 01:48am EST 

Zealand Pharma A/S : Royalty revenue from Sanofi's sales of Lyxumia (lixisenatide) outside the United states of 5.3 million Danish crowns ($760,849)/0.7 million euros ($747,040.00) for Q4 2016 .Annual royalty revenue in respect of lyxumia amounted to 24.3 million crowns/3.3 million euros in 2016.  Full Article

Zealand Pharma says patient recruitment completed for Phase II trial with glepaglutide
Monday, 6 Feb 2017 09:26am EST 

Zealand Pharma A/S : Patient recruitment completed for Phase II trial with glepaglutide for treatment of short bowel syndrome .Zealand Pharma A/S says results of Phase II trial are expected mid 2017.  Full Article

Zealand Pharma Q2 operating loss widening to DKK 88.0 million
Thursday, 25 Aug 2016 01:55am EDT 

Zealand Pharma A/S : Q2 operating loss 88.0 million Danish crowns ($13.33 million) versus loss 64.6 million crowns year ago . Q2 revenue 7.9 million crowns versus 7.3 million crowns year ago . Financial guidance for 2016 unchanged .Maintains its revenue guidance for full-year.  Full Article

Zealand Pharma announces new timelines for U.S. FDA decision on iglarlixi
Friday, 19 Aug 2016 06:28pm EDT 

Zealand Pharma A/S : Zealand announces new timelines for a U.S. FDA decision on iglarlixi, the fixed-ratio combination of lixisenatide (adlyxintm) and lantus(r), for the treatment of type 2 diabetes . Financial guidance for 2016 remains unchanged . A U.S. regulatory decision on iglarlixi is now expected before end of November 2016 .FDA requested updated information on pen delivery device for iglarlixi as part of new drug application, which was submitted by Sanofi.  Full Article

Zealand Pharma: royalty revenue of DKK 6.4 mln in Q2 on sales of Lyxumia
Friday, 29 Jul 2016 01:36am EDT 

Zealand Pharma A/S : Lixisenatide as adlyxin to treat type 2 diabetes commercial launch by Sanofi in U.S. is expected later in H2 . Royalty revenue of 6.4 million Danish crowns ($950,000)/0.9 million euros in Q2 2016 on sales of Lyxumia(Lixisenatide outside U.S.) .US FDA approved recently lixisenatide as adlyxinto treat type 2 diabetes.  Full Article

Zealand Pharma and Beta Bionics to collaborate
Friday, 10 Jun 2016 09:00am EDT 

Zealand Pharma A/S : The company and Beta Bionics to collaborate on development of first-in-class dual-hormonal bionic pancreas system for treatment of people with type 1 diabetes . Financial guidance for 2016 remains unchanged . Synergistic match of Beta Bionics' dual-hormonal, artificial, or bionic, pancreas device platform, iLet, and Zealand’s liquid stable glucagon analog, ZP4207 . Expected next step under collaboration is initiation of clinical trials in H2 2016 .In future trials, the company will evaluate a multiple-dose version of its proprietary novel glucagon analog, ZP4207, with ilet.  Full Article

More From Around the Web

BRIEF-Zealand Pharma: positive Phase 2a results with microdoses of dasiglucagon

* POSITIVE PHASE 2A RESULTS WITH MICRODOSES OF DASIGLUCAGON SUPPORT USE IN A DUAL-HORMONE ARTIFICIAL PANCREAS SYSTEM